Drug intelligence / Profile preview

RT301

Development stage: Preclinical
Lead developer: Revio Therapeutics
Modality: Drug Delivery Systems
Administration: Oral

Overview

**RT301** is a Revio Therapeutics cardiovascular reformulation program described by the sponsor as an oral fixed-dose-combination tablet. The specific active ingredients, molecular targets, and pharmacologic mechanism have not been publicly disclosed. Revio positions the program within its reformulation portfolio, which is intended to optimize delivery of established medicines for unmet clinical needs in cardiovascular disease.

Beyond the preview

Go deeper on RT301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT301.

Explore the full profile